Skip to main content
PMC home page
Gut logoLink to Gut
. 1999 Dec;45(6):812–817. doi: 10.1136/gut.45.6.812

A comparison of the therapeutic effectiveness of gastrin neutralisation in two human gastric cancer models: relation to endocrine and autocrine/paracrine gastrin mediated growth

S Watson 1, T Morris 1, A Varro 1, D Michaeli 1, A Smith 1
PMCID: PMC1727758  PMID: 10562577

Abstract

BACKGROUND—Gastrin is a growth factor for established tumours.
AIMS—To investigate the therapeutic effect of antibodies, raised against the Gastrimmune immunogen, which neutralise the glycine extended and carboxy amidated forms of gastrin 17 in two human gastric cancer models.
METHODS—MGLVA1 cells (which have a gastrin autocrine/paracrine phenotype) and ST16 cells (which have an endocrine phenotype) were injected into the peritoneal cavity of SCID mice. Peritoneal tumours, ascites, and cachexia formation occurred, with the monitored endpoint being morbidity.
RESULTS—In MGLVA1 cells, intravenous administration of antibodies raised against Gastrimmune increased the 50% median survived by 25% at three different initial cell seeding concentrations (1 × 106-5 × 105 per mouse). In ST16 cells, the effect of Gastrimmune induced antibodies on time to morbidity was greatest at the lowest cell seeding concentration (5 × 105 cells/mouse) with the 50% median survival increased by 74% and overall survival achieved in 38% of the mice.
CONCLUSIONS—Gastrimmune may have potential therapeutic benefit on gastrin sensitive gastric tumours and may interact with both endocrine and autocrine mediated growth pathways.


Keywords: gastrin; gastric cancer; Gastrimmune; autocrine/paracrine growth

Full Text

The Full Text of this article is available as a PDF (109.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

A Southern blot showing gastrin mRNA expression of MGLVA1 and ST16 cells grown in serum free conditions in vitro. The standard curve is generated with PCR products from a gastrin positive control (human G cells) of known DNA content.

Figure 2  .

Figure 2  

Open in a new tab

Effect of rabbit anti-G17 (9):DT IgG on the in vitro growth of (A) MGLVA1, and (B) ST16 in serum free growth conditions. *p<0.05. MTT, methylthiazoyl tetrazolium.

Figure 3  .

Figure 3  

Open in a new tab

Effect of Gastrimmune induced antiserum on the in vivo growth of MGLVA1 cells at three different seeding concentrations: (A) 1 × 106; (B) 7.5 × 105; (C) 5 × 105.

Figure 4  .

Figure 4  

Open in a new tab

Effect of Gastrimmune induced antiserum on the in vivo growth of ST16 cells at three different seeding concentrations: (A) 1 × 106; (B) 7.5 × 105; (C) 5 × 105.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin G. S. Binding of progastrin fragments to the 78 kDa gastrin-binding protein. FEBS Lett. 1995 Feb 6;359(1):97–100. doi: 10.1016/0014-5793(95)00017-4. [DOI] [PubMed] [Google Scholar]
  2. Ito M., Iwata N., Taniguchi T., Murayama T., Chihara K., Matsui T. Functional characterization of two cholecystokinin-B/gastrin receptor isoforms: a preferential splice donor site in the human receptor gene. Cell Growth Differ. 1994 Oct;5(10):1127–1135. [PubMed] [Google Scholar]
  3. Iwase K., Evers B. M., Hellmich M. R., Guo Y. S., Higashide S., Kim H. J., Townsend C. M., Jr Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Gastroenterology. 1997 Sep;113(3):782–790. doi: 10.1016/s0016-5085(97)70172-0. [DOI] [PubMed] [Google Scholar]
  4. Kobori O., Vuillot M. T., Martin F. Growth responses of rat stomach cancer cells to gastro-entero-pancreatic hormones. Int J Cancer. 1982 Jul 15;30(1):65–67. doi: 10.1002/ijc.2910300112. [DOI] [PubMed] [Google Scholar]
  5. Matsushima Y., Kinoshita Y., Nakata H., Inomoto-Naribayashi Y., Asahara M., Kawanami C., Nakamura A., Ito M., Matsui T., Fujiwara T. Gastrin receptor gene expression in several human carcinomas. Jpn J Cancer Res. 1994 Aug;85(8):819–824. doi: 10.1111/j.1349-7006.1994.tb02953.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. McLaughlan J. M., Seth R., Vautier G., Robins R. A., Scott B. B., Hawkey C. J., Jenkins D. Interleukin-8 and inducible nitric oxide synthase mRNA levels in inflammatory bowel disease at first presentation. J Pathol. 1997 Jan;181(1):87–92. doi: 10.1002/(SICI)1096-9896(199701)181:1<87::AID-PATH736>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  7. McWilliams D. F., Watson S. A., Crosbee D. M., Michaeli D., Seth R. Coexpression of gastrin and gastrin receptors (CCK-B and delta CCK-B) in gastrointestinal tumour cell lines. Gut. 1998 Jun;42(6):795–798. doi: 10.1136/gut.42.6.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Miyake A. A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem Biophys Res Commun. 1995 Mar 8;208(1):230–237. doi: 10.1006/bbrc.1995.1328. [DOI] [PubMed] [Google Scholar]
  9. Moyer M. P., Armstrong A., Aust J. B., Levine B. A., Sirinek K. R. Effects of gastrin, glutamine, and somatostatin on the in vitro growth of normal and malignant human gastric mucosal cells. Arch Surg. 1986 Mar;121(3):285–288. doi: 10.1001/archsurg.1986.01400030039006. [DOI] [PubMed] [Google Scholar]
  10. Nemeth J., Varro A., Bridson J., Walker R., Dockray G. J. Increased tissue concentrations of the gastrin precursor in patients treated with omeprazole. Eur J Clin Invest. 1992 Oct;22(10):638–644. doi: 10.1111/j.1365-2362.1992.tb01423.x. [DOI] [PubMed] [Google Scholar]
  11. Ochiai A., Yasui W., Tahara E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res. 1985 Nov;76(11):1064–1071. [PubMed] [Google Scholar]
  12. Seva C., Dickinson C. J., Yamada T. Growth-promoting effects of glycine-extended progastrin. Science. 1994 Jul 15;265(5170):410–412. doi: 10.1126/science.8023165. [DOI] [PubMed] [Google Scholar]
  13. Wang T. C., Koh T. J., Varro A., Cahill R. J., Dangler C. A., Fox J. G., Dockray G. J. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest. 1996 Oct 15;98(8):1918–1929. doi: 10.1172/JCI118993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Watson S. A., Clarke P. A., Smith A. M., Varro A., Michaeli D., Grimes S., Caplin M., Hardcastle J. D. Expression of CCKB/gastrin receptor isoforms in gastro-intestinal tumour cells. Int J Cancer. 1998 Aug 12;77(4):572–577. doi: 10.1002/(sici)1097-0215(19980812)77:4<572::aid-ijc17>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  15. Watson S. A., Clifford T. L., Steele R. J. Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994 Oct;5(5):591–597. doi: 10.1097/00001813-199410000-00011. [DOI] [PubMed] [Google Scholar]
  16. Watson S. A., Durrant L. G., Morris D. L. Growth-promoting action of gastrin on human colonic and gastric tumour cells cultured in vitro. Br J Surg. 1988 Apr;75(4):342–345. doi: 10.1002/bjs.1800750416. [DOI] [PubMed] [Google Scholar]
  17. Watson S. A., Durrant L. G., Morris D. L. The effect of the E2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, on the growth of a human gastric cell line, MKN45G. Int J Cancer. 1990 Jan 15;45(1):90–94. doi: 10.1002/ijc.2910450117. [DOI] [PubMed] [Google Scholar]
  18. Watson S. A., Durrant L. G., Wencyk P. M., Watson A. L., Morris D. L. Intracellular gastrin in human gastrointestinal tumor cells. J Natl Cancer Inst. 1991 Jun 19;83(12):866–871. doi: 10.1093/jnci/83.12.866. [DOI] [PubMed] [Google Scholar]
  19. Watson S. A., Michaeli D., Grimes S., Morris T. M., Crosbee D., Wilkinson M., Robinson G., Robertson J. F., Steele R. J., Hardcastle J. D. Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumour AP5. Int J Cancer. 1995 Apr 10;61(2):233–240. doi: 10.1002/ijc.2910610216. [DOI] [PubMed] [Google Scholar]
  20. Watson S. A., Michaeli D., Grimes S., Morris T. M., Robinson G., Varro A., Justin T. A., Hardcastle J. D. Gastrimmune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 1996 Feb 15;56(4):880–885. [PubMed] [Google Scholar]
  21. Watson S. A., Michaeli D., Grimes S., Morris T. M., Varro A., Clarke P. A., Smith A. M., Justin T. A., Hardcastle J. D. A comparison of an anti-gastrin antibody and cytotoxic drugs in the therapy of human gastric ascites in SCID mice. Int J Cancer. 1999 Apr 12;81(2):248–254. doi: 10.1002/(sici)1097-0215(19990412)81:2<248::aid-ijc14>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  22. Watson S., Durrant L., Morris D. Gastrin: growth enhancing effects on human gastric and colonic tumour cells. Br J Cancer. 1989 Apr;59(4):554–558. doi: 10.1038/bjc.1989.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. van Solinge W. W., Rehfeld J. F. Co-transcription of the gastrin and cholecystokinin genes with selective translation of gastrin mRNA in a human gastric carcinoma cell line. FEBS Lett. 1992 Aug 31;309(1):47–50. doi: 10.1016/0014-5793(92)80736-z. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES